Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.
about
Insulin Promoter Factor 1 variation is associated with type 2 diabetes in African Americans.Obesity and insulin resistance: an abridged molecular correlationDiabetes mellitus related bone metabolism and periodontal diseaseType 2 diabetes can be prevented with early pharmacological interventionDC260126: a small-molecule antagonist of GPR40 that protects against pancreatic β-Cells dysfunction in db/db miceIdentification of differential responses to an oral glucose tolerance test in healthy adultsEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsPrenatal androgen exposure programs metabolic dysfunction in female mice.An autosome-wide search using longitudinal data for loci linked to type 2 diabetes progressionAdiponectin and pro-inflammatory cytokines are modulated in Vietnamese patients with type 2 diabetes mellitus.Lack of lipotoxicity effect on {beta}-cell dysfunction in ketosis-prone type 2 diabetes.The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose toleranceGlucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study.Weight gain in pregnancy and risk of maternal hyperglycemia.Effects of intravenous glucose load on insulin secretion in patients with ketosis-prone diabetes during near-normoglycemia remission.Mangiferin facilitates islet regeneration and β-cell proliferation through upregulation of cell cycle and β-cell regeneration regulators.The association between serum uric acid and residual β -cell function in type 2 diabetes.A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosisThe changes in early phase insulin secretion in newly diagnosed, drug naive korean prediabetes subjects.The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic beta-cell dysfunction.Moderate diet-induced weight loss is associated with improved insulin sensitivity in middle-aged healthy obese Korean women.Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in childrenPioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Exenatide once weekly: clinical outcomes and patient satisfaction.You are what you eat, or are you? The challenges of translating high-fat-fed rodents to human obesity and diabetes.Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin.Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants.High glucose predisposes gene expression and ERK phosphorylation to apoptosis and impaired glucose-stimulated insulin secretion via the cytoskeletonThe CaMK4/CREB/IRS-2 cascade stimulates proliferation and inhibits apoptosis of β-cellsErectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177α3(V) collagen is critical for glucose homeostasis in mice due to effects in pancreatic islets and peripheral tissuesEfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Pubertal changes of insulin sensitivity, acute insulin response, and β-cell function in overweight Latino youth.Variation of C peptide decay rate in diabetic patients with positive glutamic acid decarboxylase antibody: better discrimination with initial fasting C peptidePioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinMechanism linking diabetes mellitus and obesity.Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice.The association between nonalcoholic fatty pancreas disease and diabetesHigher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
P2860
Q24812084-02CBC8D1-8813-40E1-904A-48A9642D9155Q26825473-875D5FF5-CE85-48DC-8F1D-A906C923E22CQ26852990-22709419-F922-46B9-B03A-DFB8C16D181CQ27694430-62AF7C83-3E9E-4968-8BD8-E3418475F1F7Q28533802-AE152B31-EC88-45F9-9037-8CE442BF6035Q28535572-59206021-8FC3-4F13-8B5E-BBBA0132C30FQ28732080-7E3F69D7-E910-4320-8772-776A64946FC6Q30421731-B034A4A3-B7C5-4EE1-92E2-9320E096F97CQ30907301-00955931-4A81-4B3D-A533-F94ADE6C8CB9Q33633719-478BE17A-7C0C-4E03-9645-0A2E60ACA13DQ33683768-33B7BA74-4253-4E91-87DE-CF97305D44A0Q33705046-BE7F1251-70ED-41BC-B86C-328B645F399AQ33708776-AAE327DD-A8CD-4E3E-829B-986E44DDC68EQ33730920-456D25EF-1940-483D-9F84-069845C2098AQ33751560-92A6217A-0DF0-4962-BBC3-54C6FFAF5101Q33755933-CE7B446F-B54F-4DA4-9A52-44269C9316A5Q33757756-60811F89-8391-4E01-8D82-E3609627CDDDQ33880999-72FF2065-5BB2-477D-A416-B1FF8793DAE1Q33969575-D91F8DFD-455E-434A-926B-1088FC08B1B0Q33993695-69A54C53-F48E-4A22-95CB-92B3BF412A1CQ34006475-3E44EA36-2E35-42E3-8980-321EFBDFE428Q34073469-79F4455B-5A03-4BAF-99AC-EF30B0FA9BBEQ34084580-26AAB5FB-8BED-4A96-BF3B-2B11180E474BQ34139048-DF5B99E8-44A9-47A2-9442-36CE26C6880FQ34144380-2D2AAD8C-544D-44AC-85B6-D31BBE1CA910Q34284239-426718E9-355A-4300-9ABC-9BFBAAC8D525Q34297738-83847966-93B6-49DE-BCCA-787478A22869Q34397259-6EA6C40C-6773-4B35-B698-73874EF0E891Q34425147-CD65FC5F-B0BB-4CFE-9468-073D226EAC20Q34438342-F9A7CF1C-640A-4BA3-A4E8-87134FC32B64Q34498189-4212BF94-38DC-4048-8FA9-2524A0937EAAQ34519963-B5D4BF7B-2F0F-496C-8A15-1F6F2CD49D21Q34543009-F490F13B-3026-4EC1-85D5-1E74F7B7B3EAQ34574640-42D61702-4F82-41EB-8099-2F6F6FB87EEFQ34604594-86728704-E82B-4234-8B16-7D01216B04A5Q34620604-196C14FC-CC29-4717-B12D-B35947BDC314Q34657175-CDDDC3E6-99C3-4779-86D7-3F3E1261E4D0Q34696866-3168FB94-218A-48D5-A31F-62CF48B68D51Q34720662-B1947369-5B95-4B46-98B2-FB409ED9BC85Q34726350-6B45F20E-2B49-4437-BC3D-A6E66A4086AC
P2860
Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@ast
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@en
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@nl
type
label
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@ast
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@en
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@nl
prefLabel
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@ast
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@en
Clinical review 135: The impor ...... rogression of type 2 diabetes.
@nl
P356
P1476
Clinical review 135: The impor ...... progression of type 2 diabetes
@en
P2093
P304
P356
10.1210/JCEM.86.9.7713
P407
P577
2001-09-01T00:00:00Z